EP Patent

EP3391886A1 — The use of a h3r inverse agonist for the treatment of shift work disorder

Assigned to Novartis AG · Expires 2018-10-24 · 8y expired

What this patent protects

The invention relates to the use of a H3R inverse agonist for the treatment of shift work disorder.

USPTO Abstract

The invention relates to the use of a H3R inverse agonist for the treatment of shift work disorder.

Drugs covered by this patent

pitolisant-hydrochloride (PITOLISANT HYDROCHLORIDE)

Patent Metadata

Patent number: EP3391886A1
Jurisdiction: EP
Classification: —
Expires: 2018-10-24
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.